Indogulf Q1 FY27: consolidated PAT down 38% YoY as margins compress to 1.4%
PAT -37.58% YoY · revenue -11% · margins compressing
₹168.55 Cr
-11% YoY
₹2.41 Cr
-37.58% YoY
1.42%
-0.6pp YoY
₹0.38
Indogulf Cropsciences reported consolidated Q1 FY27 (quarter ended June 30, 2026) revenue of ₹168.5 Cr, down 11.0% YoY from ₹189.4 Cr, though up 11.8% sequentially from ₹150.8 Cr in Q4 FY26. Consolidated PAT fell to ₹2.41 Cr — down 37.6% YoY from ₹3.87 Cr and down 79.2% QoQ from ₹11.61 Cr — with basic EPS at ₹0.38 versus ₹0.80 a year ago and ₹2.30 in the preceding quarter. Standalone PAT of ₹2.27 Cr fell a comparatively smaller 23.2% YoY (standalone revenue -12.3% YoY to ₹162.4 Cr), so the wider consolidated decline signals a weaker contribution from the two subsidiaries, Abhiprakash Globus Private Limited and Indogulf Cropsciences Australia Pty Ltd, versus a year ago.
Q1 FY-2027 vs prior quarters
Net profit margin compressed to 1.43% of total income from 2.03% a year ago and 7.60% in Q4 FY26 — the compression shows up even as revenue grew sequentially, so the pressure is on the cost side rather than volumes. No single expense line stands out as an outlier; the combined weight of raw-material, employee and other operating costs against a YoY-softer topline drove the squeeze. Exceptional items were negligible (~₹3 lakh, both this quarter and a year ago) and were not a factor.
The stock went into the print at ₹70.1, down 6.2% over the past month of trading.
Management expressed confidence in medium-to-long-term opportunities for the agrochemical sector, expecting gradual stabilization in industry conditions. While FY27 may see near-term volatility from weather, inventory corrections, and input costs, the company anticipates this to be balanced by firming prices and an imp
— This quarter: met
No formal analyst consensus or brokerage preview for this print turned up in a web search — Indogulf is a recently listed small-cap without established sell-side coverage, so vsStreet is unknown. The results were approved at the August 12, 2026 board meeting alongside a separate IPO fund-utilization report for the quarter, filed the same day; auditors issued an unmodified limited-review opinion on both statements. No standalone management press release accompanied the filing beyond the board-outcome letter, so there is no additional management commentary to reconcile against the print.
W1
Whether NPM recovers from 1.43% toward the 2.03-7.60% range seen in the last two quarters as the flagged input-cost/inventory pressure eases
W2
Whether management's promised 'firming prices and improved product mix' shows up in margins from Q2 FY27 onward
W3
Whether the consolidated-vs-standalone PAT gap normalizes — subsidiary (Abhiprakash Globus, Indogulf Cropsciences Australia) contribution was weaker YoY this quarter